This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Four heads of iconic U.S. enterprises face turbulent, inherited challenges with elevated investor anxiety in 2025.

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

For those looking to attain a healthy body weight in 2025, there are a few options to consider. Dr. Will Cauthen, a board-certified surgeon at the Surgery Clinic of Tupelo who specializes in abdominal ...

On Tuesday, New York Governor Kathy Hochul announced a new initiative to expand access to healthcare coverage for popular ...

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that from 2021 to 2023, those rates dropped from 41.9% to 40.3%.

Incretins like GLP-1 are used in diabetes and obesity drugs such as Mounjaro and Zepbound. However, retail sentiment on ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...